权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Development of a novel, non-hormonal female contraceptive device

开发一种新型非激素女性避孕装置

基本信息

批准号：
10602355
负责人：
Emily Man
金额：
$ 30.01万
依托单位：
VENOVA TECHNOLOGIES, INC.
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-09-21 至 2024-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10602355
关键词：
Address Adolescent Affect Anatomic Models Anatomy Barrier Contraception Businesses Cervix Uteri Clinical Trials Collaborations Contraceptive Agents Contraceptive Devices Contraceptive methods Copper Intrauterine Devices Data Development Device Designs Devices Environment Family Planning Female Female Contraceptive Devices Fertility Fertilization Funding Funding Opportunities Future Goals Grant Health Health Professional Hemorrhage High-Risk Pregnancy Hormonal Hormones Human Hysterectomy In Vitro Interruption Intrauterine Devices Investigation Lead Legal patent Low income Measures Medical Medical Device Menstrual cycle Menstrual fluid Metals Methods Mission Muscle Cramp National Institute of Child Health and Human Development Operative Surgical Procedures Outcome Pain Patients Performance Persons Phase Physiological Pregnancy Property Reproductive Health Research Resort Respiratory Diaphragm Retrieval Risk Safety Screening Result Seminal Seminal fluid Side Strategic Planning Technology Technology Transfer Test Result Testing Tissues Training United States United States Dept. of Health and Human Services United States Food and Drug Administration Uterus Vacuum Vagina Validation Woman base biomaterial compatibility birth control commercialization condoms design female fertility first-in-human hypothalamic pituitary gonadal axis improved in vitro testing in vivo innovation models and simulation multidisciplinary novel pregnancy prevention preservation pressure prevent programs reproductive screening side effect socioeconomics success unintended pregnancy women of color

项目摘要

PROJECT SUMMARY The applicant, Venova Technologies, is a woman-led medical device startup company. Venova Technologies is applying for a Small Business Technology Transfer (STTR) Phase I grant to fund development towards technical milestones that will advance the commercial potential of our patent-pending non-hormonal contraceptive device. Half of pregnancies in the United States are unintended due to inconsistent or non-use of contraceptives. Current contraceptives offer a range of options in an attempt to meet the varying needs of women at different stages of their lives. Yet many women remain dissatisfied with their options, and many discontinue use due to hormonally-related side effects. Women who discontinue use of an otherwise highly effective method are likely to resort to less effective contraceptives and increase their risk of unintended pregnancy. The only highly effective non-hormonal method is the copper intrauterine device (IUD). However, the copper IUD is associated with heavier menstrual bleeding and increased cramping. Other non-hormonal options, such as diaphragms and condoms, are considerably less effective. Although many women may prefer non-hormonal methods, the choice to avoid unwanted side effects comes with a higher risk of pregnancy. There is a critical unmet need for birth control options that are reliable, discreet, affordable, acceptable, and without adverse side effects. Venova Technologies is developing a non-hormonal long-acting reversible device to directly address the paucity of methods that are highly effective with a reduced side effective profile. Venova Technologies’ contraceptive solution does not rely on hormones or metals to achieve contraception, and it does not interfere with the hypothalamic-pituitary-gonadal axis nor interrupt natural menstrual cycles. The device is fitted and placed by a trained healthcare professional and should provide effective contraception for several years. In vitro studies confirmed proof of principle, and devices have been successfully screened and tested by a medical practitioner using hyper-realistic anatomical models. In this STTR Phase I program, Venova Technologies will further refine the functionality and performance of the contraceptive device using three screening steps in increasingly realistic environments: benchtop in vitro tests, advanced tissue-mimicking anatomical models, and ex vivo female reproductive tissues excised during surgical hysterectomies. Success in this project will increase confidence in the device design needed to proceed with in vivo studies and to pursue future grants and external funding opportunities. The device will offer women control over their fertility with a safe, discreet, long-acting, reversible, highly effective method that does not rely on hormones or metals. Venova Technologies’ mission to address the global unmet need for more non-hormonal options that are affordable and acceptable for family planning fully aligns with the NICHD Strategic Plan 2020 and has immense positive health and socioeconomic implications for women in the United States and around the world.

项目总结